Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Buy
55
PRE Quote, Financials, Valuation and Earnings
Last price:
$8.33
Seasonality move
:
-29.33%
Day range:
$7.50 - $8.46
52-week range:
$3.09 - $11.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.10x
P/B ratio:
0.58x
Volume:
16.8K
Avg. volume:
35.5K
1-year change:
27.3%
Market cap:
$99.1M
Revenue:
$30.6M
EPS (TTM):
-$3.99
Analysts' Opinion
-
Consensus RatingPrenetics Global has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.00, Prenetics Global has an estimated upside of 71.05% from its current price of $7.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $7.60.
Fair Value
-
According to the consensus of 1 analyst, Prenetics Global has 71.05% upside to fair value with a price target of $13.00 per share.
PRE vs. S&P 500
-
Over the past 5 trading days, Prenetics Global has underperformed the S&P 500 by -15.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Prenetics Global does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Prenetics Global has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Prenetics Global reported revenues of $7.8M.
Earnings Growth
-
Prenetics Global has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Prenetics Global reported earnings per share of -$0.84.
Enterprise value:
37.2M
EV / Invested capital:
--
Price / LTM sales:
3.10x
EV / EBIT:
--
EV / Revenue:
1.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.2M
Return On Assets:
-18.87%
Net Income Margin (TTM):
-183.52%
Return On Equity:
-23.16%
Return On Invested Capital:
-23.16%
Operating Margin:
-151.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $101.1M | $21.7M | $30.6M | $5.4M | $10.5M | |
| Gross Profit | $38.2M | $8.8M | $15.4M | $2.7M | $3.9M | |
| Operating Income | -$138M | -$56.5M | -$50.9M | -$10M | -$17.9M | |
| EBITDA | -$172.5M | -$60.6M | -$57.5M | -$16.5M | -$24.9M | |
| Diluted EPS | -$51.11 | -$5.78 | -$3.71 | -$1.57 | -$1.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $106.9M | $241.8M | $93.7M | $86.1M | |
| Total Assets | -- | $148.5M | $312.1M | $254.2M | $213.6M | |
| Current Liabilities | -- | $58.7M | $57.2M | $39.5M | $36.6M | |
| Total Liabilities | -- | $549.4M | $68.7M | $44M | $42.2M | |
| Total Equity | -- | -$400.9M | $243.5M | $210.2M | $171.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-12 | 2024-06-12 | 2024-06-12 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
PRE
Sector
Market Cap
$99.1M
$33.4M
Price % of 52-Week High
63.39%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
27.3%
-36.6%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.20
200-day SMA
Buy
Level
$5.17
Bollinger Bands (100)
Buy
Level
3.81 - 7.17
Chaikin Money Flow
Sell
Level
-5.7M
20-day SMA
Sell
Level
$8.34
Relative Strength Index (RSI14)
Sell
Level
49.93
ADX Line
Sell
Level
34.69
Williams %R
Neutral
Level
-68.4867
50-day SMA
Buy
Level
$6.05
MACD (12, 26)
Buy
Level
0.56
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
5.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7973)
Buy
CA Score
(Annual)
Level (-0.1203)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (2.0665)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by ‘enhancing life through science’.
Stock Forecast FAQ
In the current month, PRE has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PRE average analyst price target in the past 3 months is $13.00.
-
Where Will Prenetics Global Stock Be In 1 Year?
According to analysts, the consensus estimate is that Prenetics Global share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About Prenetics Global?
Analysts are divided on their view about Prenetics Global share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prenetics Global is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Prenetics Global's Price Target?
The price target for Prenetics Global over the next 1-year time period is forecast to be $13.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Prenetics Global is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PRE?
You can purchase shares of Prenetics Global via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prenetics Global shares.
-
What Is The Prenetics Global Share Price Today?
Prenetics Global was last trading at $8.33 per share. This represents the most recent stock quote for Prenetics Global. Yesterday, Prenetics Global closed at $7.60 per share.
-
How To Buy Prenetics Global Stock Online?
In order to purchase Prenetics Global stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 3.23% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 2.21% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.85% over the past day.
